The AUA Symptom score (AUASS) was administered for three consecutive years to participants in a national prostate cancer screening study. Although the prevalence symptom free (AUSS 0) individuals was very low (`7%) in this cohort of 16 000 men, mean AUASS and proportion of men in the mild, moderate and severe categories are equivalent to community-based studies from around the world. Across all ages and races, AUASS drops after 12 months but returns to original levels at 24 months. No differences in AUASS were noted for race when adjusted for age. Age is most strongly correlated to the increase in AUASS and to the severity of urinary symptoms.
Introduction
The American Urological Association (AUA) urinary symptom index, also known as the International Prostate Symptom Score (I-PSS), was developed to quantify symptom frequency and severity and to evaluate symptom improvement following intervention in men with benign prostatic hyperplasia (BPH). The index has been shown to be consistent and reliable, 1 but it lacks diagnostic sensitivity 2 and speci®city. 3±5 Despite limitations, the index has been used to estimate prevalence and compare the frequency of lower urinary tract symptoms among individuals. French, Japanese and Spanish versions have been validated and administered with good results, permitting comparisons among different cultural/racial populations. 6±9 Symptom scoring has also been used as a screening tool for prostate disease, but the lack of correlation with prostate volume,¯ow rates and post void residual volume has precluded its widespread use. 10 Nevertheless, several studies have shown the value of the AUA symptom score/I-PSS in epidemiological research and clinical practice.
11±14
The prevalence of urinary symptoms appears to be age-dependent. 6±9,14 Older men are more frequently symptomatic, and they also have higher AUA symptom scores. 9 The age-related increase in prevalence of lower urinary tract symptoms in the community parallels that of clinical and pathological BPH. 15, 16 Moreover, various studies have reported that some ethnic groups are more symptomatic or bothered than others. 7, 9, 17, 18 Patients with BPH also display racial differences in average AUA symptom scores: blacks have higher scores than Hispanics or whites (P`0.03), 12 but multivariate analysis in a community-based study did not demonstrate any difference in the prevalence of symptoms between black and white men, despite the fact blacks scored lower. 6 The way in which patients perceive the clinical problem of prostatism varies with their degree of awareness of their condition over time. Symptomatic patients seem to remain stable (do not worsen); some may even improve. Spontaneous, long lasting disappearance of prostatism has been reported to occur in 15±70%. 19 In one study, individual I-PSS scores tended to drop between ®rst and second visits eight weeks apart; but when the entire group was analysed the mean score did not change.
within the last four weeks, and the natural history of the disease might change within eight weeks, 11 caution must be taken into consideration when analyzing crosssectional studies on symptom prevalence.
Not much is known of the natural history of urinary symptoms for the male population that has never had either a history or any current evidence of prostate disease. In a community-based longitudinal study, Jacobsen reported a slight decrease of symptom severity at 18 months but an increase at 42 months across all ages, even though there was much variability among individuals. Overall, the net change for the entire population was an increase in symptom severity over time in accordance with the conventional knowledge of the slow progression of prostatism. 21 Nevertheless, several questions remain to be answered. Is it prevalent to have non-speci®c urinary symptoms among`healthy' males over 40 y of age? Would we expect any degree of change in voiding patterns over time, or is it just part of the normal aging process?
Prostate Cancer Awareness Week (PCAW) is one of the largest cancer screening programs in the United States. 22 In addition to promoting public awareness of prostate cancer, this program tends to recruit asymptomatic men for prostate cancer screening. A community-based, longitudinal study conducted during PCAW has accumulated records of 16 000 participants tested serially for 3 y (1993±1995). The objective of the present study is to report on the prevalence and natural history of urinary symptoms among this cohort, as determined by the AUA symptom score.
Material and methods

Study population
In 1992 a multi-year longitudinal study of prostatespeci®c antigen (PSA) was initiated during PCAW. Since 1993 the AUA symptom score was included in the participant questionnaire. Those individuals with signi®cant problems upon initial testing were recommended to seek urologic care and were dropped from the longitudinal study. From a total of 166 619 individual records with AUA scores, only 16 715 participants had three consecutive annual scores (50 145 records). Men dropped out of the study after 1 or 2 y, while others joined but were not tested in three consecutive years. Patients who initially presented with signi®cant urinary symptoms were referred to further diagnostic evaluation. Only subjects with veri®able ages between 40±89 y of age were included in the analyses. Patients with histories of prostate cancer or prostate surgery were removed. Of the 16 715 participants with three consecutive annual scores, 1004 (6%) failed to answer two or more of the seven AUA questions in any one year and were eliminated from the study. Participants who answered all but one question in any year (n 1088) were given the missing question's annual median score, a common statistical method to accommodate missing data. The ®nal data set consisted of 14 663 individuals, with 7.4% having received a substituted median score. Participants were classi®ed by age, race, and AUA symptom severity: mild (0±7), moderate (8±19) and severe (20±35). Individuals without a history of BPH or prostatitis (n 9484) were classi®ed as normal healthy males for this study and were then re-analyzed separately.
Analyses
Statistical analyses of the database were performed with SAS. 23 Descriptive statistics were generated for annual AUA scores, individual 3 y average scores, and 3 y averages by decade of age, race and symptom severity category. The Wilcoxon signed-rank test with a Bonferroni correction of a 0.0167 was used for multiple comparisons of the average AUASS across 1993, 1994 and 1995. The same test and correction was also applied when participants were further categorized by decade of life and race across the same years. When testing for differences between adjacent age decades, a Wilcoxon ranksum test with a Bonferroni correction of a 0.005 was utilized, and for races an a 0.0083. Analysis of covariance was performed on ranked average scores for models of age, race, and age-race interaction. Regression analysis on the ranked scores versus age was performed. The mean AUA score was calculated for each year of patient age. Regression analysis was also performed on these mean AUA scores. Each question's mean for each year of patient age was also tested by regression analysis. The sum of all 1995 AUA scores for each question was obtained, and a grand sum of all 1995 question scores was totaled. The contribution of each question to this grand sum is reported as a percentage. Chi-square tests were used to compare differences between proportions in the symptom severity categories for the ethnic groups.
Results
The mean age for the total cohort was 63.7 (8.76) y; the distribution of individuals by age decade is seen in Table 1 Out of the 51 375 men screened during PCAW in 1995 only 6.8% were urinary symptom free (AUASS 0). The mean AUA symptom score for the matched data set was 6.6 in 1993, 6.0 in 1994 and 6.5 in 1995. The sign-rank test indicates a clear and signi®cant drop (P`0.005) in the average AUASS at 12 months of follow-up and a signi®-cant increase (P`0.005) from 12±24 months. However, there was no difference from base line (1993) to 2 y (1995). The same change pattern of decrease and increase in the average AUASS was seen across almost all age groups and races (Table 1 ). The changes in the AUASS for each individual are summarized in Figure 1 A signi®cant linear relationship (P`0.05) was seen with ranked AUASS vs age using all 14 663 records, although there was much variability between individuals (r 2 0.03). The regression analysis of the mean AUASS for each year of patient age ( Figure 2 ) reveals a remarkable linear relation of age and AUASS (r 2 0.8334). The same test was applied for each individual question's mean score at each year of patient age. The strongest linear relationship ( Figure 3 ) was seen with age and nocturia for which r 2 0.936; but, incomplete emptying, weak stream, urgency and intermittency also had a strong linear relationship with age (r 2 0.762; 0.742; 0.718; 0.608, respectively). Hesitancy and frequency had the weakest relationship (r 2 0.448 and 0.320 respectively) but were still signi®cantly related (P`0.05). The percentages by which each individual question affects the total AUASS for 1995 is shown in Figure 4 . A signi®cant difference (P`0.001) in AUASS was found between all adjacent age cohorts except between the 70±79 to 80±89 age decades. Observance of the means for each cohort show scores steadily increasing with age (Table 1 ). Prevalence and natural history of urinary symptoms J Stenner et al
African-Americans and whites were found to have a signi®cant difference (P`0.005) in their average AUASS in all years. Blacks consistently scored the lowest AUASS. No difference was noted in any of the comparisons between other ethnic groups, although in some years the average scores of Hispanic and/or Asian populations were higher than for whites (Table 1) . A multivariate analysis showed that, although race affects AUASS the predominant in¯uencing factor is age (P`0.001). Also, no signi®cant difference was seen between the proportions of each of the symptom severity categories (mild, moderate, severe) within the different ethnic groups, indicating that there is no predisposition of any race to any given category (Table 2) .
For the total population (Table 3) , the proportion of individuals in the mild, moderate and severe categories were 64.9%, 32.2% and 2.9%, respectively. A comparative analysis of the proportions for each symptom severity category among different reported series can be observed in Table 4 . The average AUASS for the mild category was 3.16, for moderate 11.32 and for severe 22.59. Table 2 also shows the proportions for each year, race and age decade.
The mean AUASS for`normal' participants was 5.28 in 1993, 4.76 in 1994 and 5.23 for 1995; and the median score was 3, 3 and 4, respectively. Because the percentage of normal men with near zero differences is large (57%) the signed rank test results may be compromised. In this instance, the paired t-test was substituted for the Wilcoxon signed rank test; no signi®cant difference was obtained. The same pattern of signi®cant difference in scores across age cohorts is seen in the normal group of men as was for the entire study population.
Comment
Although the study population was comprised of selfselected individuals attending a prostate cancer screening program, the prevalence of urinary symptoms or the average AUA scores and the percentage of men within each symptom severity category parallels those from community-based cross-sectional and longitudinal studies (Tables  3 and 4) . Analysis of the results should be interpreted in light of the potential impact of the group analyzed.
Across all ages (40 y) among various populations, the symptom-free population (AUASS of 0) is very low. In France, the sampled population showed only 18.8% symptom-free, while in Spain 14.9% had no symptoms and in the Netherlands 12%. 6, 7, 9 Out of the total population screened in 1995 during Prostate Cancer Awareness Week only 6.8% were symptom-free. Therefore, the majority of this population, when asked, had some degree of non-speci®c urinary symptoms. The very low percentage of symptom-free individuals in this study could be due to the fact that these individuals attended the screening study because they do have more urinary symptoms, but this is not supported by the fact that their average AUASS does not vary greatly from those other studies. 4±6,9,14,21 Other possible explanations for differences to percentages reported in other studies are differences in methodology, using a translated version of the questionnaire, cultural perceptions of normal voiding patterns or that American men may be more likely to report symptoms.
The mean AUA score varies among reported community-based studies. For our population, the average AUASS for the 3 y was 6.36. That varies considerably with the Scottish score of 3.78; but it is almost identical with that of 6.34 in Olmsted County, Minnesota. 18 It is also in accord with Lepor's study of unselected males surveyed at a health care fair, with an average AUASS of 6.7. 4 Even though all of these studies differ greatly in methodology, the mean AUA score remains the same for the American populations. Nonetheless, mild symptomatic BPH patients have an average AUASS of 6.3.
11
Based only on symptoms, this subgroup of patients parallels the average male population for whom no treatment is advocated. Furthermore, our mean AUA score of 4 at baseline may differ from the median in Japan of 8 and 5 from Olmsted County, but when adjusted for non-responders, these medians drop to 5 and 4 respectively, which means that our sampled population is not much different from their community-based studies. Prevalence and natural history of urinary symptoms J Stenner et al
Whether the AUASS is self-administered, intervieweradministered, or asked within directed interviews, urinary symptoms among aging male populations show an initial decrease in the average symptom score, even if administered 1, 2, or 4 weeks or 18 months apart. This phenomenon is seen in the evaluation of symptomatic BPH patients and in the longitudinal evaluation of the prevalence and natural history of urinary symptoms among community based populations. 11, 20, 21 Of course, the magnitude of change seen in this normal population is lower than that in symptomatic patients. We see a statistically signi®cant decrease in the AUASS at 12 months but a signi®cant increase from 12±24 months. Overall, a nonsigni®cant change was observed. The population analyzed may have become familiar with the questions asked and/or once the fear of cancer diagnosis had been removed they may tend to report fewer symptoms or less severity. Symptom frequency or severity may stabilize in the short term, but with enough time the average AUASS will follow its aging trend as observed in our age categories.
In the evaluation of clinical trials for the treatment of BPH the natural history of urinary symptoms must be considered and the outcome judged over at least 2 y, after having administered at least one questionnaire during that time. If evaluated at 1 y only, a statistically signi®cant degree of improvement may be observed, but this may be just a natural phenomenon. This could also explain, to some extent, the reported placebo effect or`spontaneous improvement' of symptoms in some patients. Table 4 demonstrates cultural differences in the percentage of individuals within each of the symptom severity category. Although dif®cult to compare symptom scores from different studies, due to varying methodologies, the French population 7 is similar to the healthy young control group, with a mean of 39 y of age, utilized by Barry et al 1 to validate the AUA symptom index. Due to sampling and inclusion and exclusion criteria, the French symptomatic population may be underrepresented. The overall proportions from our study of a combined moderate and severe categories of 35.1% are not much different from Lepor's 4 
series in Wisconsin and
Tsukamoto's 8 in Japan with 36% and 36.6%, respectively. They are also similar to the Spanish (30.4%) and Dutch (30%) populations. 6, 9 The age-related increase in the frequency of urinary symptoms has been well documented. 5, 8, 14, 15, 21 Age is the major factor in changing voiding patterns. Across all ages (40±70 y old cohorts) a signi®cant increase (P`0.005) in the average AUASS, except for the 8th and 9th decades of life, is observed but with no statistically signi®cant difference. The average AUASS of 4.91 for the 40±49 y age group increased to 7.97 in the 80±89 y age group (Table 1) . Nevertheless, considerable variation between individuals is observed among the average AUASS for each year of patient age (r 2 0.8). The impact of aging is clear. Not only does the average AUASS increase, but so does the proportion of patients in the moderate and severe categories. The proportion of individuals moving from the mild category to the moderate or severe is approximately 6.5% per each age decade. An additional 20% of the total population will eventually move to categories in which a treatment for urinary symptoms is usually required ( Table 2) .
The increase in the average AUASS with age is due to the increase in the average response to each individual question, with nocturia showing the clearest trend with age, as also noticed by Jacobsen. 21 The obstructive and irritative symptoms account almost equally to the total symptoms score, with no particular group of symptoms having greater age dependence.
Although a statistically signi®cant difference exists between blacks and whites in their average AUASS, no difference was found between whites and other ethnic groups or between blacks and Hispanics or Asians. This difference between blacks and whites was also noticed by Moon, in which blacks had a lower average AUASS. 5 In the analysis of covariance, only age was signi®cant (P 0.0001). Blacks have similar proportions of individuals in the mild, moderate and severe category ( Table 2) . There is no statistically signi®cant difference between races in any category (w 2 test). Cultural differences may be more important than race. The proportion of individuals within the symptom severity category for our Hispanic population parallels that of the community-based study in Spain, 68.7% vs 69.6% for mild, 27.2% vs 24.2% for moderate and 4.1% vs 6.2% for severe. 6 The proportion of the combined mild and severe categories in Japan 8 (36.6%) is also similar to that of our Asian population (40.3%).
Excluding individuals with a history of prostatitis and BPH, a`normal' population emerges. This group has an average AUASS of 5.09 (4.43), an expected proportion of 75% in the mild category and 25% in the moderate-severe categories. The same¯uctuation of average AUASS is seen with this group, but in a 2 y period we con®rm no change. Nevertheless, aging increases the mean AUASS and the proportions of moderate and severe categories to the same extent as the entire study group. Likewise as expected, no difference between the races was seen in this population (data not shown).
Conclusions
It is common for the aging male to have non-speci®c urinary symptoms, as demonstrated by the fact that there was a very low percentage (`7%) of symptom free (AUASS 0) individuals in our population. There is a signi®cant drop in the average AUA symptom score at 12 months and a signi®cant increase at 24 months, but overall, non-signi®cant change. With enough time the average AUASS will follow its aging trend. Obstructive and irritative symptoms have equal impact on the total AUASS; nevertheless, the increase in the average AUASS with age is due to the increase in the average response to each individual question. In the voiding pattern of our population race is not an important contributor and any differences may be due to cultural factors. Aging is the main contributor in the increase of the average AUASS and in the severity of urinary symptoms. Normal males after 40 y of age have a median AUA score of three. Uncontrolled treatment studies should be adjusted for age and for the degree of expected change across time.
